S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
OTCMKTS:IMLFF

InMed Pharmaceuticals Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
$4.88
$4.96
52-Week Range
N/A
Volume
63,800 shs
Average Volume
11,369 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Receive IMLFF News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


About InMed Pharmaceuticals

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, it works on IND-enabling pharmacology and preclinical toxicology studies. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

Headlines

What You Need To Know About CBD Hash
September 6, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:IMLFF
CIK
N/A
Fax
N/A
Employees
4
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












InMed Pharmaceuticals (OTCMKTS:IMLFF) Frequently Asked Questions

Who are InMed Pharmaceuticals' key executives?

InMed Pharmaceuticals' management team includes the following people:
  • Mr. Eric A. Adams, Pres, CEO & Director (Age 56)
  • Mr. Bruce S. Colwill C.A., CPA, CA, CFO & Corp. Sec. (Age 55)
  • Ms. Alexandra D. J. Mancini, Sr. VP of Clinical & Regulatory Affairs (Age 67)
  • Dr. Eric Chih-Hsien Hsu, Sr. VP of Preclinical R&D (Age 50)
  • Mr. Michael Woudenberg P.Eng., VP of Chemistry, Manufacturing & Controls (Age 53)
  • Dr. Sazzad Hossain, Co-Founder
  • Mr. Brendan Payne, Director of Investor Relations
  • Mr. Richard Hoy, VP of Sales & Marketing
  • Dr. Ado Muhammad, Sr. Consultant of Medical Affairs

What is InMed Pharmaceuticals' stock symbol?

InMed Pharmaceuticals trades on the OTCMKTS under the ticker symbol "IMLFF."

How do I buy shares of InMed Pharmaceuticals?

Shares of IMLFF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How many employees does InMed Pharmaceuticals have?

InMed Pharmaceuticals employs 4 workers across the globe.

What is InMed Pharmaceuticals' official website?

The official website for InMed Pharmaceuticals is www.inmedpharma.com.

How can I contact InMed Pharmaceuticals?

The company can be reached via phone at (604) 669-7207.


This page was last updated on 12/5/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.